Inhibition of C-reactive protein induced expression of matrix metalloproteinases by atorvastatin in THP-1 cells

Molecular and Cellular Biochemistry

Volumn 338, Issue 1-2, 2010, Pages 77-86

  Mahajan, Nitin ^a   Dhawan, Veena ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Atorvastatin; C reactive protein; MAPK; MMPs; TIMP 1

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; FC RECEPTOR; FC RECEPTOR IIB; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; PYRROLE DERIVATIVE;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MONOCYTE; PHYSIOLOGY;

ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEPTANOIC ACIDS; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASES; MONOCYTES; PYRROLES; RECEPTORS, IGG; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 77951295436     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-009-0340-x     Document Type: Article

References (48)

1. E Paffen MPK de Maat 2006 C-reactive protein in atherosclerosis: a causal factor? Cardiovasc Res 71 30 39 10.1016/j.cardiores.2006.03.004 1:CAS:528:DC%2BD28Xls1eitro%3D 16624260 (Pubitemid 43870060)
2. RS Packard P Libby 2008 Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction Clin Chem 54 24 38 10.1373/clinchem.2007.097360 1:CAS:528:DC%2BD1cXmtFelsg%3D%3D 18160725 (Pubitemid 351182593)
3. PM Ridker N Rifai L Rose JE Buring NR Cook 2002 Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 1557 1565 10.1056/NEJMoa021993 1:CAS:528:DC%2BD38Xos1KhsL0%3D 12432042 (Pubitemid 35315836)
4. J Cermak NS Key RR Bach J Balla HS Jacob GM Vercellotti 1993 C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor Blood 82 513 520 1:CAS:528:DyaK3sXlsFOltrY%3D 8329706
5. TN Williams CX Zhang BA Game L He Y Huang 2004 C-reactive protein stimulates MMP-1 expression in U937 histiocytes through Fc[gamma]RII and extracellular signal-regulated kinase pathway: an implication of CRP involvement in plaque destabilization Arterioscler Thromb Vasc Biol 24 61 66 10.1161/01.ATV.0000104014.24367.16 1:CAS:528:DC%2BD3sXhtVWhurnJ 14592848 (Pubitemid 38082412)
6. N Abe T Osanai T Fujiwara K Kameda T Matsunaga K Okumura 2006 C-reactive protein-induced up-regulation of extracellular matrix metalloproteinase inducer in macrophages: Inhibitory effect of fluvastatin Life Sci 78 1021 1028 10.1016/j.lfs.2005.06.015 1:CAS:528:DC%2BD28XmsFamtA%3D%3D 16182316 (Pubitemid 43112542)
7. A Nabata M Kuroki H Ueba S Hashimoto T Umemoto H Wada T Yasu M Saito S Momomura M Kawakami 2008 C-reactive protein induces endothelial cell apoptosis and matrix metalloproteinase-9 production in human mononuclear cells: implications for the destabilization of atherosclerotic plaque Atherosclerosis 196 129 135 10.1016/j.atherosclerosis.2007.03.003 1:CAS:528: DC%2BD1cXpt1yrsQ%3D%3D 17531242
8. Mahajan N, Bahl A, Dhawan V (2009) C-reactive protein (CRP) up-regulates the expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of Atorvastatin. Int J Cardiol. doi: 10.1016/j.ijcard.2009.01.008
9. V Pasceri HD Wu JT Willerson 2004 Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators Circulation 101 235 238
10. SK Venugopal S Devaraj I Yuhanna P Shaul I Jialal 2002 Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells Circulation 106 1439 1441 10.1161/01.CIR.0000033116.22237.F9 1:CAS:528:DC%2BD38XntVKksLg%3D 12234944
11. S Verma SH Li MV Badiwala RD Weisel PWM Fedak RK Li B Dhillon DAG Mickle 2002 Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein Circulation 105 1890 1896 10.1161/01.CIR.0000015126.83143.B4 1:CAS:528:DC%2BD38XktFajtbY%3D 11997273 (Pubitemid 34437614)
12. CH Wang SH Li RD Weisel PWM Fedak AS Dumont P Szmitko Li Ren-Ke DAG Mickle S Verma 2003 C-reactive protein up-regulates angiotensin type 1 receptors in vascular smooth muscle Circulation 107 1783 1790 10.1161/01.CIR.0000061916. 95736.E5 1:CAS:528:DC%2BD3sXisFaju7o%3D 12665485 (Pubitemid 36418360)
13. R Ross 1999 Atherosclerosis-an inflammatory disease NEJM 340 115 126 10.1056/NEJM199901143400207 1:STN:280:DyaK1M%2FptFSqtQ%3D%3D 9887164 (Pubitemid 29054847)
14. P Libby M Aikawa 2002 Stabilization of atherosclerotic plaques: new mechanisms and clinical targets Nat Med 8 1257 1262 10.1038/nm1102-1257 1:CAS:528:DC%2BD38XotlWmu7s%3D 12411953 (Pubitemid 35373557)
15. R Lee 1997 The unstable atheroma Arterioscler Thromb Vasc Biol 17 1859 1867 1:STN:280:DyaK1c%2Fht1Kquw%3D%3D 9351346
16. MJ Davies 1998 Reactive oxygen species, metalloproteinases, and plaque stability Circulation 97 2382 2383 1:STN:280:DyaK1czgtleruw%3D%3D 9641687
17. ZS Galis KG Sukhova MAW Lark P Libby 1994 Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques J Clin Invest 94 2493 2503 10.1172/JCI117619 1:CAS:528:DyaK2MXisFWgsrg%3D 7989608
18. JPM Cleutjiens JC Kandala E Guarda RV Guntak KT Weber 1995 Regulation of collagen degradation in the rat myocardium after infarction J Mol Cell Cardiol 27 1281 1292 10.1016/S0022-2828(05)82390-9
19. AC Newby 2006 Do metalloproteinases destabilize vulnerable atherosclerotic plaques? Curr Opin Lipidol 17 556 561 10.1097/01.mol.0000245262. 48258.b4 1:CAS:528:DC%2BD28XptF2rtLc%3D 16960505 (Pubitemid 44372687)
20. JD Raffetto RA Khalil 2008 Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease Biochem Pharmacol 75 346 359 10.1016/j.bcp.2007.07.004 1:CAS:528:DC%2BD1cXhsVynsg%3D%3D 17678629 (Pubitemid 350298459)
21. IM Loftus 2000 Increased matrix MMP-9 activity in unstable carotid plaques. A potential role in acute plaque disruption Stroke 31 40 47 1:CAS:528:DC%2BD3cXmsVGiuw%3D%3D 10625713
22. H Kai H Ikeda H Yasukawa M Kai Y Seki F Kuwahara T Ueno K Sugi T Imaizumi 1998 Peripheral blood of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes J Am Coll Cardiol 32 368 372 10.1016/S0735-1097(98)00250-2 1:STN:280:DyaK1cznt1WltQ%3D%3D 9708462 (Pubitemid 28396484)
23. Y Inokubo 2001 Plasma levels of matrix MMP-9 and TIMP-1 are increased in the coronary circulation in patients with acute coronary syndromes Am Heart J 141 217 10.1067/mhj.2001.112238 (Pubitemid 32128725)
24. T Force CM Pombo AJ Avruch 1996 Stress activated protein kinases in cardiovascular disease Circ Res 78 947 953 1:CAS:528:DyaK28Xjt1Gktrk%3D 8635244
25. S Kumar J Boehm JC Lee 2003 p38 MAPKs: key signalling molecules as therapeutic targets for inflammatory diseases Nat Rev Drug Discov 2 717 726 10.1038/nrd1177 1:CAS:528:DC%2BD3sXmvVWlsbw%3D 12951578
26. AJ Muslin 2008 MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets Clin Sci 115 203 218 10.1042/CS20070430 1:CAS:528:DC%2BD1cXhtVGktLrM 18752467
27. SP Ballou G Lozanski 1992 Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein Cytokine 4 361 368 10.1016/1043-4666(92)90079-7 1:CAS:528:DyaK3sXmt1Cisbw%3D 1420997
28. Blum A, Shamburek R (2008) The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. doi: 10.1016/j.atherosclerosis.2008.08.022
29. WL Hu SB Qian JJ Li 2002 Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin Cytokine 40 201 206 10.1016/j.cyto.2007.09.011
30. E Kibayashi M Urakaze C Kobashi M Kishida M Takata A Sato K Yamazaki M Kobayashi 2005 Inhibitory effect of pitavastatin (NK-104) on the C-reactive protein-induced interleukin-8 production in human aortic endothelial cells Clin Sci 108 515 521 10.1042/CS20040315 1:CAS:528:DC%2BD2MXks1Gltbc%3D 15701058 (Pubitemid 40827559)
31. N Mahajan V Dhawan G Sharma S Jain D Kaul 2008 Induction of inflammatory gene expression by THP-1 macrophages cultured in normocholesterolemic hypertensive sera and modulatory effects of green tea polyphenols J Hum Hypertens 22 141 143 10.1038/sj.jhh.1002277 1:CAS:528:DC%2BD1cXnt1eqsA%3D%3D 17728801
32. KH Han KH Hong JH Park J Ko DH Kang KJ Choi MK Hong SW Park SJ Park 2004 CRP promotes MCP-1 mediated chemotaxis through upregulating CCR2 expression in human monocytes Circulation 109 2566 2571 10.1161/01.CIR.0000131160.94926.6E 1:CAS:528:DC%2BD2cXkt1ars7o%3D 15136507 (Pubitemid 38720558)
33. G Doronzo I Russo L Mattiello M Trovati G Anfossi 2005 C-reactive protein increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells J Lab Clin Med 146 287 298 10.1016/j.lab.2005.07. 010 1:CAS:528:DC%2BD2MXhtFers7nL 16242528 (Pubitemid 41464406)
34. TC Major L Liang X Lu W Rosebury TMA Bocan 2002 Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma Arterioscler Thromb Vasc Biol 22 1200 1207 10.1161/01.ATV.0000021411.53577.1C 1:CAS:528:DC%2BD38XlsFSgt7w%3D 12117738 (Pubitemid 34764874)
35. S Rajagopalan XP Meng S Ramasamy DG Harrison ZS Galis 1996 Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability J Clin Invest 98 2572 2579 10.1172/JCI119076 1:CAS:528:DyaK28XnsVWnt78%3D 8958220
36. K Yasojima C Schwab EG Mc Geer PL Mc Geer 2001 Generation of C-reactive protein and complement components in atherosclerotic plaques Am J Pathol 158 1039 1051 1:CAS:528:DC%2BD3MXitlOmsr0%3D 11238052
37. J Torzewski M Torzewski DE Bowyer M Fröhlich W Koenig J Waltenberger C Fitzsimmons V Hombach 1998 C-reactive protein frequently co-localizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries Arterioscler Thromb Vasc Biol 18 1386 1392 1:CAS:528:DyaK1cXmtlyitbo%3D 9743226
38. AP Burke FD Kolodgie A Zieske DR Fowler DK Weber VP Jacob F Andrew R Virmani 2004 Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study Arterioscler Thromb Vasc Biol 24 1266 1271 10.1161/01.ATV.0000131783.74034.97 1:CAS:528:DC%2BD2cXlt1WlurY%3D 15142859 (Pubitemid 38880019)
39. NR Ratcliffe SM Kennedy PM Morganelli 2001 Immunocytochemical detection of FcγR in human atherosclerotic lesions Immunol Lett 2001 77 169 174 10.1016/S0165-2478(01)00217-6 (Pubitemid 32532072)
40. J Ryu CW Lee JA Shin CS Park JJ Kim SJ Park KH Han 2007 FcgammaRIIa mediates C-reactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4 Cardiovasc Res 75 555 565 10.1016/j.cardiores.2007.04.027 1:CAS:528:DC%2BD2sXot1ykt7Y%3D 17531211 (Pubitemid 47080970)
41. Devaraj S, Dasu MR, Singh U, Rao LVM, Jialal I (2008) C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis. doi: 10.1016/j.atherosclerosis.2008.05.060
42. J Wu MJ Stevenson JM Brown EA Grunz TL Strawn WP Fay 2008 C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance Arterioscler Thromb Vasc Biol 28 698 704 10.1161/ATVBAHA.107.160903 1:CAS:528:DC%2BD1cXjt1Slt7c%3D 18276908 (Pubitemid 351651347)
43. R Lin J Liu W Gan G Yang 2004 C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells Biol Pharm Bull 27 1537 1543 10.1248/bpb.27.1537 1:CAS:528:DC%2BD2cXhtFSit7fP 15467191 (Pubitemid 41701635)
44. Y Ichida G Hasegawa M Fukui H Obayashi M Ohta A Fujinami K Ohta K Nakano T Yoshikawa N Nakamura 2006 Effect of Atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes Pharmacol 76 34 39 10.1159/000088948 1:CAS:528:DC%2BD2MXht1Oqt7jK (Pubitemid 41759059)
45. G Qiu JS Hill 2007 Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages J Lipid Res 48 2112 2122 10.1194/jlr.M600510-JLR200 1:CAS:528:DC%2BD2sXhtFemtL7N 17644777 (Pubitemid 47529554)
46. M Takata M Urakaze R Temaru K Yamazaki N Nakamura Y Nobata M Kishida A Sato M Kobayashi 2001 Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase Br J Pharmacol 134 753 762 10.1038/sj.bjp.0704305 1:CAS:528:DC%2BD3MXotlChsLk%3D 11606315
47. AP Negre AK Van Viiet M Van Erck GC Van Thiel RE Van Leeuwen LH Cohen 1997 Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types Biochim Biophys Acta 1345 259 268
48. Y Kashiwagi T Haneda J Osaki S Miyata K Kikuchi 1998 Mechanical stretch activates a pathway linked to mevalonate metabolism in cultured neonatal rat heart cells Hypertens Res 21 109 119 10.1291/hypres.21.109 1:CAS:528: DyaK1cXksFahtL4%3D 9661807